Antipsychotic drugs prevent the motor hyperactivity induced by psychotomimetic MK-801 in zebrafish (Danio rerio)

Behavioural Brain Research

Volumn 214, Issue 2, 2010, Pages 417-422

  Seibt, Kelly Juliana ^a   Oliveira, Renata da Luz ^a   Zimmermann, Fernanda Francine ^a   Capiotti, Katiúcia Marques ^a   Bogo, Maurício Reis ^a,b   Ghisleni, Gabriele ^a   Bonan, Carla Denise ^a,b  

^a PONTIFICAL CATHOLIC UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b National Institute for Translational Medicine INCT TM   (Brazil)

Author keywords

Antipsychotics; Anxiety; Locomotor activity; MK 801; Schizophrenia; Zebrafish

Indexed keywords

DIZOCILPINE; HALOPERIDOL; OLANZAPINE; SULPIRIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY; ARTICLE; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; HYPERACTIVITY; LOCOMOTION; MALE; NONHUMAN; PRIORITY JOURNAL; TRANQUILIZING ACTIVITY; ZEBRA FISH;

ANIMALS; ANTIPSYCHOTIC AGENTS; DIZOCILPINE MALEATE; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; HALLUCINOGENS; HYPERKINESIS; MALE; MOTOR ACTIVITY; ZEBRAFISH;

EID: 77955274181     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2010.06.014     Document Type: Article

References (73)

1. Adams B.W., Moghaddam B. Effect of clozapine, haloperidol, or M100907 on phencyclidine-activated glutamate efflux in the prefrontal cortex. Biol Psychiatry 2001, 50:750-757.
2. Adams C.E., Coutinho E.S., Davis J., Duggan L., Leucht S., Li C., et al. Cochrane schizophrenia group. Schizophr Bull 2008, 34:259-265.
3. Aghajanian G.K., Marek G.J. Serotonin, via 5-HT2A receptors, increases EPSCs in layer V pyramidal cells of prefrontal cortex by an asynchronous mode of glutamate release. Brain Res 1999, 825:161-171.
4. Akwa Y., Purdy R.H., Koob G.F., Britton K.T. The amygdala mediates the anxiolytic-like effect of the neurosteroid allopregnanolone in rat. Behav Brain Res 1999, 106:119-125.
5. Austin J. Schizophrenia: an update and review. J Genet Couns 2005, 14:329-340.
6. Bertoglio L.J., Carobrez A.P. Anxiolytic-like effects of NMDA/glycine-B receptor ligands are abolished during the elevated plus-maze trial 2 in rats. Psychopharmacology (Berl) 2003, 170:335-342.
7. Best J.D., Alderton W.K. Zebrafish: an in vivo model for the study of neurological diseases. Neuropsychiatr Dis Treat 2008, 4:567-576.
8. Bitran D., Klibansky D.A., Martin G.A. The neurosteroid pregnanolone prevents the anxiogenic-like effect of inescapable shock in the rat. Psychopharmacology (Berl) 2000, 151:31-37.
9. Brot M.D., Akwa Y., Purdy R.H., Koob G.F., Britton K.T. The anxiolytic-like effects of the neurosteroid allopregnanolone: interactions with GABA(A) receptors. Eur J Pharmacol 1997, 325:1-7.
10. Brustein E., Saint-Amant L., Buss R.R., Chong M., McDearmid J.R., Drapeau P. Steps during the development of the zebrafish locomotor network. J Physiol (Paris) 2003, 97:77-86.
11. Bubenikova-Valesova V., Svoboda J., Horacek J., Vales K. The effect of a full agonist/antagonist of the D1 receptor on locomotor activity, sensorimotor gating and cognitive function in dizocilpine-treated rats. Int J Neuropsychopharmacol 2009, 1-11.
12. Carlsson M., Carlsson A. Interactions between glutamatergic and monoaminergic systems within the basal ganglia-implications for schizophrenia and Parkinson's disease. Trends Neurosci 1990, 13:272-276.
13. Chartoff E.H., Heusner C.L., Palmiter R.D. Dopamine is not required for the hyperlocomotor response to NMDA receptor antagonists. Neuropsychopharmacology 2005, 30(1):324-333.
14. Clineschmidt B.V., Martin G.E., Bunting P.R., Papp N.L. Central sympathomimetic activity of (+)-5-methyl-10,11-dihydro-5H-dibenzo [d]cyclohepten-5,10-immine(MK-801), a substance with potent anticonvulsant, central sympathomimetic, and apparent anxiolytic properties. Drug Dev Res 1982, 2:135-145.
15. Corbett R., Camacho F., Woods A.T., Kerman L.L., Fishkin R.J., Brooks K., et al. Antipsychotic agents antagonize non-competitive N-methyl-d-aspartate antagonist-induced behaviors. Psychopharmacology (Berl) 1995, 120:67-74.
16. Deutsch S.I., Rosse R.B., Mastropaolo J. Behavioral approaches to the functional assessment of NMDA-mediated neural transmission in intact mice. Clin Neuropharmacol 1997, 20:375-384.
17. Dunn R.W., Corbett R., Fielding S. Effects of 5-HT1A receptor agonists and NMDA receptor antagonists in the social interaction test and the elevated plus maze. Eur J Pharmacol 1989, 169:1-10.
18. Fetcho J.R., Bhatt D.H. Genes and photons: new avenues into the neuronal basis of behavior. Curr Opin Neurobiol 2004, 14:707-714.
19. Flyckt L., Sydow O., Bjerkenstedt L., Edman G., Rydin E., Wiesel F.A. Neurological signs and psychomotor performance in patients with schizophrenia, their relatives and healthy controls. Psychiatry Res 1999, 86:113-129.
20. Gattaz W.F., Schummer B., Behrens S. Effects of zotepine, haloperidol and clozapine on MK-801-induced stereotypy and locomotion in rats. J Neural Transm Gen Sect 1994, 96:227-232.
21. Gerlai R., Fernandes Y., Pereira T. Zebrafish (Danio rerio) responds to the animated image of a predator: towards the development of an automated aversive task. Behav Brain Res 2009, 201:318-324.
22. Gerlai R., Lahav S., Guo S., Rosenthal A. Drinks like a fish: zebra fish (Danio rerio) as a behavior genetic model to study alcohol effects. Pharmacol Biochem Behav 2000, 67:773-782.
23. Geyer M.A., Krebs-Thomson K., Braff D.L., Swerdlow N.R. Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology (Berl) 2001, 156:117-154.
24. Geyer M.A., Moghaddam B. Animal models relevant to schizophrenia disorders. Neuropsychopharmacology: the fifth generation of progress 2002, 689-701. Lippincott Williams & Wilkins, Washington, DC. K.L. Davis, D. Charney, J.T. Coyle, C. Nemeroff (Eds.).
25. Giacomini N.J., Rose B., Kobayashi K., Guo S. Antipsychotics produce locomotor impairment in larval zebrafish. Neurotoxicol Teratol 2006, 28:245-250.
26. Guo S. Linking genes to brain, behavior and neurological diseases: what can we learn from zebrafish?. Genes Brain Behav 2004, 3:63-74.
27. Ichikawa J., Kuroki T., Dai J., Meltzer H.Y. Effect of antipsychotic drugs on extracellular serotonin levels in rat medial prefrontal cortex and nucleus accumbens. Eur J Pharmacol 1998, 351:163-171.
28. Irons T.D., Macphail R.C., Hunter D.L., Padilla S. Acute neuroactive drug exposures alter locomotor activity in larval zebrafish. Neurotoxicol Teratol 2010, 32:84-90.
29. Jentsch J.D., Roth R.H. The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 1999, 20:201-225.
30. Jones D.N.C., Gartlon J.E., Minassian A., Perry W., Geyer M. Developing new drugs for schizophrenia: from animals to the clinic. Animal and translational models for CNS drug discovery volume 1: psychiatric disorders 2008, 199-261. Elsevier, New York. R.A. McArthur, F. Borsini (Eds.).
31. Kane J.M. Schizophrenia. N Engl J Med 1996, 334:34-41.
32. Karcz-Kubicha M., Jessa M., Nazar M., Plaznik A., Hartmann S., Parsons C.G., et al. Anxiolytic activity of glycine-B antagonists and partial agonists-no relation to intrinsic activity in the patch clamp. Neuropharmacology 1997, 36:1355-1367.
33. Kari G., Rodeck U., Dicker A.P. Zebrafish: an emerging model system for human disease and drug discovery. Clin Pharmacol Ther 2007, 82:70-80.
34. Kiang M., Daskalakis Z.J., Christensen B.K., Remington G., Kapur S. Actigraphic measurement of the effects of single-dose haloperidol and olanzapine on spontaneous motor activity in normal subjects. J Psychiatry Neurosci 2003, 28:293-299.
35. Kilts C.D. The changing roles and targets for animal models of schizophrenia. Biol Psychiatry 2001, 50:845-855.
36. Laruelle M., Abi-Dargham A. Dopamine as the wind of the psychotic fire: new evidence from brain imaging studies. J Psychopharmacol 1999, 13:358-371.
37. Levin E.D., Bencan Z., Cerutti D.T. Anxiolytic effects of nicotine in zebrafish. Physiol Behav 2007, 90:54-58.
38. Leysen J.E., Janssen P.M., Megens A.A., Schotte A. Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity. J Clin Psychiatry 1994, 55:5-12.
39. Lindenmayer J.P., Nathan A.M., Smith R.C. Hyperglycemia associated with the use of atypical antipsychotics. J Clin Psychiatry 2001, 62:30-38.
40. Majewska M.D. Steroid regulation of the GABAA receptor: ligand binding, chloride transport and behaviour. Ciba Found Symp 1990, 153:83-97.
41. Manschreck T.C., Maker B.A., Candela S.F. Earlier age of first diagnosis in schizophrenia is related to impaired motor control. Schizophr Bull 2004, 30:351-360.
42. Marquis J.P., Audet M.C., Doré F.Y., Goulet S. Delayed alternation performance following subchronic phencyclidine administration in rats depends on task parameters. Prog Neuropsychopharmacol 2007, 31:1108-1112.
43. Marx C.E., VanDoren M.J., Duncan G.E., Lieberman J.A., Morrow A.L. Olanzapine and clozapine increase the GABAergic neuroactive steroid allopregnanolone in rodents. Neuropsychopharmacology 2003, 28:1-13.
44. Marx C.E., Shampine L.J., Duncan G.E., VanDoren M.J., Grobin A.C., Massing M.W., et al. Clozapine markedly elevates pregnenolone in rat hippocampus, cerebral cortex, and serum: candidate mechanism for superior efficacy?. Pharmacol Biochem Behav 2006, 84:598-608.
45. McClelland G.R., Cooper S.M., Pilgrim A.J. A comparison of the central nervous system effects of haloperidol, chlorpromazine and sulpiride in normal volunteers. Br J Clin Pharmacol 1990, 30:795-803.
46. McCreadie R.G., Srinivasan T.N., Padmavati R., Thara R. Extrapyramidal symptoms in unmedicated schizophrenia. J Psychiatr Res 2005, 39:261-266.
47. McKeown K.A., Downes G.B., Hutson L.D. Modular laboratory exercises to analyze the development of zebrafish motor behavior. Zebrafish 2009, 6:179-185.
48. Moghaddam B., Adams B., Verma A., Daly D. Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci 1997, 17:2921-2927.
49. Murray J. Phencyclidine (PCP): a dangerous drug, but useful in schizophrenia research. J Psychol 2002, 136:319-327.
50. Newcomer J.W., Farber N.B., Jevtovic-Todorovic V., Selke G., Melson A.K., Hershey T., et al. Ketamine-induced NMDA receptor hypofunction as a model of memory impairment and psychosis. Neuropsychopharmacology 1999, 20:106-118.
51. Ninan I., Kulkarni S.K. Preferential inhibition of dizocilpine-induced hyperlocomotion by olanzapine. Eur J Pharmacol 1999, 368:1-7.
52. Olney J.W., Newcomer J.W., Farber N.B. NMDA receptor hypofunction model of schizophrenia. J Psychiatr Res 1999, 33:523-533.
53. O'Neill M.F., Shaw G. Comparison of dopamine receptor antagonists on hyperlocomotion induced by cocaine, amphetamine, MK-801 and the dopamine D1 agonist C-APB in mice. Psychopharmacology (Berl) 1999, 145:237-250.
54. Parikh V., Terry A.V., Khan M.M., Mahadik S.P. Modulation of nerve growth factor and choline acetyltransferase expression in rat hippocampus after chronic exposure to haloperidol, risperidone, and olanzapine. Psychopharmacology 2004, 172:365-374.
55. Parng C., Seng W.L., Semino C., McGrath P. Zebrafish: a preclinical model for drug screening. Assay Drug Dev Technol 2002, 1:41-48.
56. Patton E.E., Zon L.I. The art and design of genetic screens: zebrafish. Nat Rev Genet 2001, 2:956-966.
57. Peralta V., Cuesta M.J. Motor features in psychotic disorders. II. Development of diagnostic criteria for catatonia. Schizophr Res 2001, 47:117-126.
58. Porsolt R.D., Moser P.C., Castagne V. Behavioral indices in antipsychotic drug discovery. J Pharmacol Exp Ther 2010, 333:632-638.
59. Ridler K., Veijola J.M., Tanskanen P., Miettunen J., Chitnis X., Suckling J., et al. Fronto-cerebellar systems are associated with infant motor and adult executive functions in healthy adults but not in schizophrenia. Proc Natl Acad Sci USA 2006, 103:15651-15656.
60. Rujescu D., Bender A., Keck M., Hartmann A.M., Ohl F., Raeder H., et al. A pharmacological model for psychosis based on N-methyl-d-aspartate receptor hypofunction: molecular, cellular, functional and behavioral abnormalities. Biol Psychiatry 2006, 59:721-729.
61. Seibt K.J., Oliveira R.L., Rico E.P., Dias R.D., Bogo M.R., Bonan C.D. Typical and atypical antipsychotics alter acetylcholinesterase activity and ache expression in zebrafish (Danio rerio) brain. Comp Biochem Physiol C 2009, 150:10-15.
62. Seillier A., Giuffrida A. Evaluation of NMDA receptor models of schizophrenia: divergences in the behavioral effects of sub-chronic PCP and MK-801. Behav Brain Res 2009, 204:410-415.
63. Senger M.R., Rosemberg D.B., Rico E.P., Arizi M.B., Dias R.D., Bogo M.R., et al. In vitro effect of zinc and cadmium on acetylcholinesterase and ectonucleotidase activities in zebrafish (Danio rerio) brain. Toxicol In Vitro 2006, 20:954-958.
64. Simpson S.M., Menard J.L., Reynolds J.N., Beninger R.J. Post-weaning social isolation increases activity in a novel environment but decreases defensive burying and subchronic MK-801 enhances the activity but not the burying effect in rats. Pharmacol Biochem Behav 2010, 95:72-79.
65. Snyder S.H. Amphetamine psychosis: a 'model' schizophrenia mediated by catecholamines. Am J Psychiatry 1973, 130:61-67.
66. Su Y.A., Si T.M., Zhou D.F., Guo C.M., Wang X.D., Yang Y., et al. Risperidone attenuates MK-801-induced hyperlocomotion in mice via the blockade of serotonin 5-HT2A/2C receptors. Eur J Pharmacol 2007, 564:123-130.
67. Sumanasa S., Lin S. Zebrafish as a model system for drug target screening and validation. Drug Discov Today Targets 2004, 3:89-96.
68. Swain H.A., Sigstad C., Scalzo F.M. Effects of dizocilpine (MK-801) on circling behavior, swimming activity, and place preference in zebrafish (Danio rerio). Neurotoxicol Teratol 2004, 26:725-729.
69. Taylor D.M., McAskill R. Atypical antipsychotics and weight gain-a systemic review. Acta Psychiatr Scand 2000, 101:416-432.
70. Voruganti L., Cortese L., Ouyewumi L., Cernovsky Z., Zirul S., Awad A. Comparative evaluation of conventional and new antipsychotic drugs with reference to their subjective tolerability, side effect profile and impact on quality of life. Schizophr Res 2000, 43:135-145.
71. Westerfield M. The zebrafish book 2007, University of Oregon Press, Eugene. 5th ed.
72. Whitty P., Clarke M., Browne S., McTigue O., Kamali M., Feeney L., et al. Prospective evaluation of neurological soft signs in first-episode schizophrenia in relation to psychopathology: state versus trait phenomena. Psychol Med 2003, 33:1479-1484.
73. Wong A.H., Van Tol H.H. Schizophrenia: from phenomenology to neurobiology. Neurosci Biobehav Rev 2003, 27:269-306.